Tapimmune Inc (TPIV) 0.6100 $TPIV
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.80 (-0.18), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)
TapImmune to Present at Aegis Capital 2015 Growth Conference in Las Vegas on October 9, 2015
PR Newswire - Wed Oct 07, 7:30AM CDT
TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured as a presenting company at the Aegis Capital Corp. 2015 Growth Conference, at the Encore Wynn Hotel in Las Vegas, Nevada which takes place October 7-9, 2015. The presentation will be on Friday, October 9th, 1:30-2:00 PST in Brahms 1.
Global Smallpox Pipeline Review, H2 2015 - 10 Companies & 12 Drug Profiles
M2 - Tue Oct 06, 10:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x94bpm/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bavarian Nordic A/S - CEL-SCI Corporation - Chimerix, Inc. - EpiVax, Inc. - Nanotherapeutics, Inc. - Oncovir, Inc. - SIGA Technologies, Inc. - Symphogen A/S - TapImmune Inc. - Tonix Pharmaceuticals Holding Corp. Drug Profiles - 24a - brincidofovir - CEL-1000 - cidofovir - imatinib mesylate - Monoclonal Antibodies for Infectious Disease - PL-801 - Poly-ICLC - Sym-002 - tecovirimat - TPIV-300 - VIR-002 For more information visit http://www.researchandmarkets.com/research/x94bpm/smallpox
TNXP: 6.99 (+0.01), CMRX: 37.40 (-0.19), CVM: 0.72 (-0.02)
SeeThruEquity Issues Company Update on TapImmune Highlighting Clinical Program Updates and Recent Financing
ACCESSWIRE - Mon Sep 28, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / September 28, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
Biotech Briefing: Positive Results in Clinical Research & Trials Playing Important Role in Advanced Development of Drug Treatment Therapies for Various Diseases and Rare Conditions
M2 - Tue Sep 22, 2:10AM CDT
A series of encouraging clinical test trial results and the latest therapeutic advancements for drug therapies may be leading to the trend that the outlook for the biotech sector is still bright. Recent trending biotech companies in focus are Q BioMed Inc (OTC: QBIO), Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Can-Fite BioPharma Ltd. (NYSE: CANF), Inotek Pharmaceuticals Corp (NASDAQ: ITEK) and TapImmune, Inc. (OTC: TPIV).
CANF: 4.20 (-0.07), ITEK: 9.63 (-0.03), AERI: 18.87 (+0.09)
Successful Results in Clinical Trials Playing Important Role in Advanced Development of Therapeutic Drug Treatments for Various Diseases and Conditions
PR Newswire - Mon Sep 21, 7:40AM CDT
A series of encouraging clinical test trial results and the latest therapeutic advancements for drug therapies may be leading to the trend that the outlook for the biotech sector is still bright. Recent trending biotech companies in focus are Q BioMed Inc (OTC: QBIO), Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Can-Fite BioPharma Ltd. (NYSE: CANF), Inotek Pharmaceuticals Corp (NASDAQ: ITEK) and TapImmune, Inc. (OTC: TPIV).
CANF: 4.20 (-0.07), ITEK: 9.63 (-0.03), AERI: 18.87 (+0.09)
Tech Stocks Hold Leading Role After Recent Market Turn Around
ACCESSWIRE - Wed Sep 16, 6:30AM CDT
CORAL GABLES, FL / ACCESSWIRE / September 16, 2015 / The Fed minutes aren't the only thing being talked about in the market. Tech stocks have helped to lead a day of strong buying on Wall Street during Tuesday's session. This marked the last full day of trading prior to what will be an intently watched meeting of the Federal Reserve's interest-rate-setting Open Market Committee. Even the tech-focused Nasdaq composite index rose by 1.14%, to 4,860.52 up another 54.76.
TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer
PR Newswire - Tue Sep 15, 7:30AM CDT
TapImmune, Inc. (OTCMKTS: TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S. Department of Defense. This grant, commencing September 15, 2015, will cover the costs for a 280 patient Phase II Clinical Trial of Folate Receptor Alpha Vaccine in patients with Triple Negative Breast Cancer.
TapImmune To Provide Update On and Confirmation Of Phase II Clinic Trial Initiation
PR Newswire - Thu Sep 10, 9:11AM CDT
TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company will hold a conference call on Wednesday, September 16 at 11:00 AM EDT to discuss recent progress in its clinical programs and financing.
TapImmune Inc to Present at the SeeThruEquities Fall
PR Newswire - Tue Sep 08, 7:00AM CDT
TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured as a presenting company at the SeeThruEquity Fall MicroCap Investor Conference. The presentation will take place Thursday, September 10th, 1.30-2.00 p.m. in Pershing Hub, Convene Grand Central, 101 Park Avenue, New York, NY 10178. The presentation will be given by Dr. John Bonfiglio, Strategic Advisor and Director of TapImmune.
At the Forefront of Immunology: WSA Interviews Immune Pharma and TapImmune
Marketwired - Wed Aug 19, 10:10AM CDT
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) CEO Dr. Daniel Teper took time to update investors on the company's recent license agreement for AmiKet Nano as well as initiation of two Phase II clinical studies with bertilimumab, their lead monoclonal antibody. The first study targets ulcerative colitis and the second study is in bullous pemphigoid which is an autoimmune skin disease. In addition, Dr. Teper discussed some of the other indications and possible applications for bertilimumab and talked about IMNP's seasoned management team. He stated that the company expects further clinical data in the next six to eighteen months.
PED: 0.28 (+0.01), IMNP: 1.28 (+0.02)
TapImmune announces transfer of IND from the Mayo Clinic
M2 - Wed Aug 19, 5:43AM CDT
Immunotherapy company TapImmune (OtherOTC:TPIV) said on Tuesday that it has acquired the Mayo Clinic IND (Investigational New Drug Application) to TapImmune under a licensing agreement.
TapImmune Completes Transfer of IND From The Mayo Clinic
PR Newswire - Tue Aug 18, 7:30AM CDT
TapImmune, Inc. (OTCQB: TPIV), a clinical stage immunotherapy company, specializing in the development of innovative technologies for the treatment of metastatic cancer, announced today the successful conveyance of the Mayo Clinic IND (Investigational New Drug Application) to TapImmune as part of the recently completed licensing agreement. The transfer marks a critical step in reaching the Company's major milestone of initiating TapImmune's sponsored Phase 2 trials in patients with triple-negative breast cancer or ovarian cancer.
TapImmune Appoints John N. Bonfiglio, Ph.D., to its Board of Directors
PR Newswire - Thu Jul 30, 7:30AM CDT
TapImmune Inc. (OTCMKTS: TPIV) is pleased to announce the appointment of John N. Bonfiglio, Ph.D., MBA to its Board of Directors. Since February, 2015 Dr. Bonfiglio has been a Strategic Advisor to the management team assisting with financing, development, and implementation of an improved Capital Markets and Shareholder IR/PR program.
ARGS: 5.80 (-0.18)
TapImmune Announces Finalization of License Agreement With Mayo Clinic To Commercialize a Folate Receptor Alpha Vaccine for Multiple Cancer Indications
PR Newswire - Mon Jul 27, 7:30AM CDT
TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company, is pleased to announce that the Company has exercised its option agreement with Mayo Clinic. TapImmune has signed a worldwide exclusive license agreement to commercialize a proprietary folate receptor alpha vaccine technology for all cancer indications. This technology, developed in the laboratory of Keith Knutson, Ph.D., at Mayo, has successfully completed Phase I clinical trials in ovarian and triple-negative breast cancer.
Penny Stocks Alerts for Liquidmetal Technologies, MaryJane Group, Thinspace Technology, Pharmacyte Biotech, COIN CITADEL, and Local Corporation
PR Newswire - Tue Jun 30, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Liquidmetal Technologies (OTCMKTS:LQMT), MaryJane Group (OTCMKTS:MJMJ), Thinspace Technology (OTCMKTS:THNS), Pharmacyte Biotech (OTCMKTS
MCB), COIN CITADEL (OTCMKTS:CCTL), and Local Corporation (NASDAQ:LOCM).
LOCM: 0.09 (+0.03)
Penny Stocks Reports for TapImmune, Axiom, DRONE AVIATION, TOTALLY HEMP CRAZY, EKSO BIONICS HOLDING, and Arrayit
PR Newswire - Mon Jun 29, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: TapImmune (OTCMKTS:TPIV), Axiom (OTCMKTS:AXMM), DRONE AVIATION (OTCMKTS
RNE), TOTALLY HEMP CRAZY (OTCMKTS:THCZ), EKSO BIONICS HOLDING (OTCBB:EKSO), and Arrayit (OTCMKTS:ARYC).
The Wealthy Biotech Trader's New Feature Pick Runs Over 150% After Announcement - Traders are Calling it the Next PPCH 3,200%+ Runner
ACCESSWIRE - Thu Jun 25, 10:42AM CDT
WINDSOR, ON / ACCESSWIRE / June 25, 2015 / The Wealthy Biotech Trader (or "WBT"
, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves, would like to report on the recent move PositiveID (OTC: PSID) has made in the market. WBT reiterates PositiveID (OTC: PSID) as their pick for the summer and into the fall.
ADXS: 11.07 (+0.83)
Penny Stocks Alerts for TOTALLY HEMP CRAZY, TapImmune, Root9b Technologies, EKSO BIONICS HOLDING, Propanc Health Group, and Dominovas Energy
PR Newswire - Thu Jun 25, 7:49AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: TOTALLY HEMP CRAZY (OTCMKTS:THCZ), TapImmune (OTCMKTS:TPIV), Root9b Technologies (OTCMKTS:RTNB), EKSO BIONICS HOLDING (OTCBB:EKSO), Propanc Health Group (OTCMKTS PCH), and Dominovas Energy (OTCMKTS NRG).
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.80 (-0.18), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)
TapImmune to Present at Aegis Capital 2015 Growth Conference in Las Vegas on October 9, 2015
PR Newswire - Wed Oct 07, 7:30AM CDT
TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured as a presenting company at the Aegis Capital Corp. 2015 Growth Conference, at the Encore Wynn Hotel in Las Vegas, Nevada which takes place October 7-9, 2015. The presentation will be on Friday, October 9th, 1:30-2:00 PST in Brahms 1.
Global Smallpox Pipeline Review, H2 2015 - 10 Companies & 12 Drug Profiles
M2 - Tue Oct 06, 10:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x94bpm/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bavarian Nordic A/S - CEL-SCI Corporation - Chimerix, Inc. - EpiVax, Inc. - Nanotherapeutics, Inc. - Oncovir, Inc. - SIGA Technologies, Inc. - Symphogen A/S - TapImmune Inc. - Tonix Pharmaceuticals Holding Corp. Drug Profiles - 24a - brincidofovir - CEL-1000 - cidofovir - imatinib mesylate - Monoclonal Antibodies for Infectious Disease - PL-801 - Poly-ICLC - Sym-002 - tecovirimat - TPIV-300 - VIR-002 For more information visit http://www.researchandmarkets.com/research/x94bpm/smallpox
TNXP: 6.99 (+0.01), CMRX: 37.40 (-0.19), CVM: 0.72 (-0.02)
SeeThruEquity Issues Company Update on TapImmune Highlighting Clinical Program Updates and Recent Financing
ACCESSWIRE - Mon Sep 28, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / September 28, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
Biotech Briefing: Positive Results in Clinical Research & Trials Playing Important Role in Advanced Development of Drug Treatment Therapies for Various Diseases and Rare Conditions
M2 - Tue Sep 22, 2:10AM CDT
A series of encouraging clinical test trial results and the latest therapeutic advancements for drug therapies may be leading to the trend that the outlook for the biotech sector is still bright. Recent trending biotech companies in focus are Q BioMed Inc (OTC: QBIO), Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Can-Fite BioPharma Ltd. (NYSE: CANF), Inotek Pharmaceuticals Corp (NASDAQ: ITEK) and TapImmune, Inc. (OTC: TPIV).
CANF: 4.20 (-0.07), ITEK: 9.63 (-0.03), AERI: 18.87 (+0.09)
Successful Results in Clinical Trials Playing Important Role in Advanced Development of Therapeutic Drug Treatments for Various Diseases and Conditions
PR Newswire - Mon Sep 21, 7:40AM CDT
A series of encouraging clinical test trial results and the latest therapeutic advancements for drug therapies may be leading to the trend that the outlook for the biotech sector is still bright. Recent trending biotech companies in focus are Q BioMed Inc (OTC: QBIO), Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Can-Fite BioPharma Ltd. (NYSE: CANF), Inotek Pharmaceuticals Corp (NASDAQ: ITEK) and TapImmune, Inc. (OTC: TPIV).
CANF: 4.20 (-0.07), ITEK: 9.63 (-0.03), AERI: 18.87 (+0.09)
Tech Stocks Hold Leading Role After Recent Market Turn Around
ACCESSWIRE - Wed Sep 16, 6:30AM CDT
CORAL GABLES, FL / ACCESSWIRE / September 16, 2015 / The Fed minutes aren't the only thing being talked about in the market. Tech stocks have helped to lead a day of strong buying on Wall Street during Tuesday's session. This marked the last full day of trading prior to what will be an intently watched meeting of the Federal Reserve's interest-rate-setting Open Market Committee. Even the tech-focused Nasdaq composite index rose by 1.14%, to 4,860.52 up another 54.76.
TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer
PR Newswire - Tue Sep 15, 7:30AM CDT
TapImmune, Inc. (OTCMKTS: TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S. Department of Defense. This grant, commencing September 15, 2015, will cover the costs for a 280 patient Phase II Clinical Trial of Folate Receptor Alpha Vaccine in patients with Triple Negative Breast Cancer.
TapImmune To Provide Update On and Confirmation Of Phase II Clinic Trial Initiation
PR Newswire - Thu Sep 10, 9:11AM CDT
TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company will hold a conference call on Wednesday, September 16 at 11:00 AM EDT to discuss recent progress in its clinical programs and financing.
TapImmune Inc to Present at the SeeThruEquities Fall
PR Newswire - Tue Sep 08, 7:00AM CDT
TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured as a presenting company at the SeeThruEquity Fall MicroCap Investor Conference. The presentation will take place Thursday, September 10th, 1.30-2.00 p.m. in Pershing Hub, Convene Grand Central, 101 Park Avenue, New York, NY 10178. The presentation will be given by Dr. John Bonfiglio, Strategic Advisor and Director of TapImmune.
At the Forefront of Immunology: WSA Interviews Immune Pharma and TapImmune
Marketwired - Wed Aug 19, 10:10AM CDT
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) CEO Dr. Daniel Teper took time to update investors on the company's recent license agreement for AmiKet Nano as well as initiation of two Phase II clinical studies with bertilimumab, their lead monoclonal antibody. The first study targets ulcerative colitis and the second study is in bullous pemphigoid which is an autoimmune skin disease. In addition, Dr. Teper discussed some of the other indications and possible applications for bertilimumab and talked about IMNP's seasoned management team. He stated that the company expects further clinical data in the next six to eighteen months.
PED: 0.28 (+0.01), IMNP: 1.28 (+0.02)
TapImmune announces transfer of IND from the Mayo Clinic
M2 - Wed Aug 19, 5:43AM CDT
Immunotherapy company TapImmune (OtherOTC:TPIV) said on Tuesday that it has acquired the Mayo Clinic IND (Investigational New Drug Application) to TapImmune under a licensing agreement.
TapImmune Completes Transfer of IND From The Mayo Clinic
PR Newswire - Tue Aug 18, 7:30AM CDT
TapImmune, Inc. (OTCQB: TPIV), a clinical stage immunotherapy company, specializing in the development of innovative technologies for the treatment of metastatic cancer, announced today the successful conveyance of the Mayo Clinic IND (Investigational New Drug Application) to TapImmune as part of the recently completed licensing agreement. The transfer marks a critical step in reaching the Company's major milestone of initiating TapImmune's sponsored Phase 2 trials in patients with triple-negative breast cancer or ovarian cancer.
TapImmune Appoints John N. Bonfiglio, Ph.D., to its Board of Directors
PR Newswire - Thu Jul 30, 7:30AM CDT
TapImmune Inc. (OTCMKTS: TPIV) is pleased to announce the appointment of John N. Bonfiglio, Ph.D., MBA to its Board of Directors. Since February, 2015 Dr. Bonfiglio has been a Strategic Advisor to the management team assisting with financing, development, and implementation of an improved Capital Markets and Shareholder IR/PR program.
ARGS: 5.80 (-0.18)
TapImmune Announces Finalization of License Agreement With Mayo Clinic To Commercialize a Folate Receptor Alpha Vaccine for Multiple Cancer Indications
PR Newswire - Mon Jul 27, 7:30AM CDT
TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company, is pleased to announce that the Company has exercised its option agreement with Mayo Clinic. TapImmune has signed a worldwide exclusive license agreement to commercialize a proprietary folate receptor alpha vaccine technology for all cancer indications. This technology, developed in the laboratory of Keith Knutson, Ph.D., at Mayo, has successfully completed Phase I clinical trials in ovarian and triple-negative breast cancer.
Penny Stocks Alerts for Liquidmetal Technologies, MaryJane Group, Thinspace Technology, Pharmacyte Biotech, COIN CITADEL, and Local Corporation
PR Newswire - Tue Jun 30, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Liquidmetal Technologies (OTCMKTS:LQMT), MaryJane Group (OTCMKTS:MJMJ), Thinspace Technology (OTCMKTS:THNS), Pharmacyte Biotech (OTCMKTS
MCB), COIN CITADEL (OTCMKTS:CCTL), and Local Corporation (NASDAQ:LOCM). LOCM: 0.09 (+0.03)
Penny Stocks Reports for TapImmune, Axiom, DRONE AVIATION, TOTALLY HEMP CRAZY, EKSO BIONICS HOLDING, and Arrayit
PR Newswire - Mon Jun 29, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: TapImmune (OTCMKTS:TPIV), Axiom (OTCMKTS:AXMM), DRONE AVIATION (OTCMKTS
RNE), TOTALLY HEMP CRAZY (OTCMKTS:THCZ), EKSO BIONICS HOLDING (OTCBB:EKSO), and Arrayit (OTCMKTS:ARYC). The Wealthy Biotech Trader's New Feature Pick Runs Over 150% After Announcement - Traders are Calling it the Next PPCH 3,200%+ Runner
ACCESSWIRE - Thu Jun 25, 10:42AM CDT
WINDSOR, ON / ACCESSWIRE / June 25, 2015 / The Wealthy Biotech Trader (or "WBT"
, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves, would like to report on the recent move PositiveID (OTC: PSID) has made in the market. WBT reiterates PositiveID (OTC: PSID) as their pick for the summer and into the fall. ADXS: 11.07 (+0.83)
Penny Stocks Alerts for TOTALLY HEMP CRAZY, TapImmune, Root9b Technologies, EKSO BIONICS HOLDING, Propanc Health Group, and Dominovas Energy
PR Newswire - Thu Jun 25, 7:49AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: TOTALLY HEMP CRAZY (OTCMKTS:THCZ), TapImmune (OTCMKTS:TPIV), Root9b Technologies (OTCMKTS:RTNB), EKSO BIONICS HOLDING (OTCBB:EKSO), Propanc Health Group (OTCMKTS
PCH), and Dominovas Energy (OTCMKTS NRG). 
